Xofluza® (baloxavir marboxil), a first-in-class, single-dose oral medicine, for the treatment of influenza,
12 Gennaio 2021
The European Commission (EC) has approved Xofluza® (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above. In addition, the
